Trials / Withdrawn
WithdrawnNCT03291353
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Michael Boyiadzis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-arm, pilot trial to evaluate the immune effects, safety and tolerability of pembrolizumab in subjects newly diagnosed with acute myeloid leukemia (AML) who have persistent leukemia after induction chemotherapy. Patients must have an ECOG performance status of 0-1. The enrollment target for this study is 10 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pembrolizumab | 200 mg IV given every three weeks |
Timeline
- Start date
- 2017-10-17
- Primary completion
- 2019-08-19
- Completion
- 2022-08-19
- First posted
- 2017-09-25
- Last updated
- 2019-04-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03291353. Inclusion in this directory is not an endorsement.